Xeris Biopharma Holdings, Inc.XERSNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-7.10%
↓ 219% below average
Average (34q)
5.98%
Historical baseline
Range
High:78.03%
Low:-46.49%
Volatility
2081.8%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -7.10% |
| Q2 2025 | 3.90% |
| Q1 2025 | 27.27% |
| Q4 2024 | 3.46% |
| Q3 2024 | 2.24% |
| Q2 2024 | -26.36% |
| Q1 2024 | 22.55% |
| Q4 2023 | 26.78% |
| Q3 2023 | -17.30% |
| Q2 2023 | 25.82% |
| Q1 2023 | -2.36% |
| Q4 2022 | -18.00% |
| Q3 2022 | 62.53% |
| Q2 2022 | -40.51% |
| Q1 2022 | -38.01% |
| Q4 2021 | 78.03% |
| Q3 2021 | 5.20% |
| Q2 2021 | 33.51% |
| Q1 2021 | -21.10% |
| Q4 2020 | 31.84% |
| Q3 2020 | -26.72% |
| Q2 2020 | -20.42% |
| Q1 2020 | -46.49% |
| Q4 2019 | -19.96% |
| Q3 2019 | -19.73% |
| Q2 2019 | 46.83% |
| Q1 2019 | 6.27% |
| Q4 2018 | 13.93% |
| Q3 2018 | 25.33% |
| Q2 2018 | -0.40% |
| Q1 2018 | 32.44% |
| Q4 2017 | 14.90% |
| Q3 2017 | 36.28% |
| Q2 2017 | 14.72% |
| Q1 2017 | 0.00% |